Australia to consider further regulation of complementary productsBMJ 2008; 336 doi: https://doi.org/10.1136/bmj.39598.494942.DB (Published 05 June 2008) Cite this as: BMJ 2008;336:1270
- Bob Burton
The Australian government is considering further regulation of the $A2bn (£970m; €1.2bn; $1.9bn) a year complementary medicines industry after a consumer group raised concerns that products are promoted despite a lack of independently assessed evidence on their effectiveness.
In May the Australian Consumers Association published a general overview of the studies of glucosamine to treat osteoarthritis. The association concluded that some glucosamine products were at best on a par with a placebo and at worst ineffective. Australian consumers are estimated to spend approximately $A49m on these supplements a year.
Symbion Health, a company …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial